Rajiv Malik has been recently appointed to board of the Mylan Inc., one of the largest pharmaceutical companies in the world. He is one of the most successful pharmaceutical professionals of Indian origin and is part of growing list of the Indians, who have achieved top positions in the best global companies.

A post - graduate of Punjab University, Malik started his career with Ranbaxy in 1983 as Research Manager for Product Development. Over the next 20 years, he worked across product development and regulatory affairs, eventually becoming the Vice President as Head of Pharma Research & Global Regulatory Affairs. He is one of the pioneers in bringing Indian generic pharmaceutical industry to the world map as he led registration of Ranbaxy’s generics in USA, the biggest pharmaceutical market in the world. After brief stints in Sandoz as head of global development & registration and Matrix Laboratories as CEO, Malik joined Mylan Inc in 2007 as Executive Vice President – Head of Global Technical operations.

Malik has accomplished a lot in his 30 years of professional career. He established Mylan Laboratories (formerly Matrix) as a leader in antiretroviral (ARV) active pharmaceutical ingredients (API) and finished dosage forms (FDFs), particularly second-line ARVs. At Sandoz, he oversaw a network of eight development centers worldwide with around 1,000 scientists and a budget of approximately $250 million. In his initial years at Mylan, he led integrations of Mylan and Matrix and the generics business of Merck KGaA in partnership with Heather Bresch and senior management to leverage the benefits of global scale and vertical integration.

With strong hold on both strategic decision and attention to operational minutiae, he oversaw Mylan’s expansion into new commercial markets, drove collaboration with Biocon on biologics and with NATCO on glatiramer, acquired and monetized strategic assets from Pfizer and Bioniche, and successfully undertook internal operational excellence in global supply chain and product portfolio management.

Within a short span of six years at Mylan, he is President and a member of the board of directors, with responsibilities spanning research and development, manufacturing operations and strategy, supply chain, medical affairs as well as the sales and marketing of Mylan’s generics business. He is also a member of Mylan’s senior executive compliance committee.